Asia Pacific Colistin Market Analysis and Forecast by Size, Share, Growth, Trends 2034

The Asia Pacific Colistin Market size is expected to reach US$ 139.9 Million by 2034 from US$ 89.5 Million in 2025. The market is estimated to record a CAGR of 5.2% from 2026 to 2034.

Executive Summary and Asia Pacific Colistin Market Analysis:

The colistin market in Asia Pacific is driven by a rising burden of multidrug-resistant (MDR) Gram-negative bacterial infections across the region, where colistin serves as a critical last-resort antibiotic for treating severe cases such as bloodstream infections (BSI), sepsis, and lower respiratory tract infections (LRTI) in hospitals. According to the World Health Organization (WHO), the Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2023 indicates that carbapenem-resistant Enterobacterales (CRE) rates in Asia Pacific averaged 30-50% in reporting countries, with MDR Klebsiella pneumoniae exceeding 60% in many settings, driving demand for colistin injectables (IV/IM) in hospital pharmacies for treating urinary tract infections (UTIs) and ventilator-associated pneumonia (VAP). In 2024, WHO data showed a 5-10% increase in MDR Acinetobacter baumannii and Pseudomonas aeruginosa in key countries, boosting colistin utilization for cystic fibrosis and tracheobronchitis. In 2025, WHO projections anticipated sustained high resistance, contributing to the increased use of colistin. New product developments include the WHO-supported 2024 regional guidelines for colistin stewardship, promoting colistin-sparing alternatives such as aztreonam-avibactam in facilities across Asia Pacific to improve safety for central nervous system infections. Other instances encompass national AMR action plans in multiple countries ), which reported a 4% rise in colistin prescriptions for human health in 2024, according to national health ministries. The WHO Regional Office for Southeast Asia's 2025 AMR update supports nebulized inhalation solutions for VAP and topical formulations for skin infections via retail pharmacies. Additionally, the 2025 WHO One Health framework emphasizes oral formulations for gastrointestinal infections in animals through online pharmacies, addressing bowel decontamination amid the silent AMR pandemic in the region.

Asia Pacific Colistin Market: Strategic Insights

Asia Pacific Colistin Market Segmentation Analysis:

• By Formulation, the Asia Pacific Colistin Market is segmented into Injectables (IV or IM), Oral, Topical Formulations, and Inhalation Solutions. The Injectables (IV or IM) segment dominated the market in 2025.
• By Indication, the Asia Pacific Colistin Market is segmented into Human Health and Animal Health. The Human Health segment dominated the market in 2025.
• By Human Health, the Asia Pacific Colistin Market is segmented into Bloodstream Infections (BSI) and Sepsis Lower, Respiratory Tract Infections (LRTI), Urinary Tract Infections (UTIs), Central Nervous System Infections, Skin Infections, Cystic Fibrosis, Tracheobronchitis or VAP, Gastrointestinal Infections, and Bowel Decontamination. The Respiratory Tract Infections (LRTI) segment dominated the market in 2025.
• By Distribution Channel, the Asia Pacific Colistin Market is segmented into Hospital Pharmacy, Retail Pharmacy, Online Channel, and Other Distribution Channel. The Hospital Pharmacy segment dominated the market in 2025.

Asia Pacific Colistin Market Players Density: Understanding Its Impact on Business Dynamics

The Asia Pacific Colistin Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.

Asia Pacific Colistin Market Outlook

The colistin market presents substantial opportunities for expansion in Asia Pacific, driven by escalating antimicrobial resistance (AMR) rates and increasing demand for last-resort antibiotics in the human and veterinary sectors. High population density, intensive livestock farming, and suboptimal antibiotic stewardship have fueled MDR Gram-negative infections, positioning colistin as a critical therapeutic option. For instance, Asia accounts for over half of the 4.71 million global AMR-associated deaths in 2021, with projections of 2.4 million annual deaths in South Asia and 1.94 million combined in Southeast Asia, East Asia, and Oceania by 2050. In China, colistin resistance in Acinetobacter baumannii reached 32.7%, while in India, it was 1.28% overall but higher in specific strains; Thailand reported 3.3%. The region holds a substantial market share, with Asia Pacific anticipated to dominate due to high MDR prevalence and expanding healthcare infrastructure. 

In Vietnam, rapid livestock growth boosts veterinary colistin demand. At the same time, in China, despite a 2017 ban on growth promotion, therapeutic use persists amid rising resistance. AMR-related costs in Asia are expected to reach US$ 550–700 billion by 2050, with additional healthcare expenditures of 2.5–10%. Investments in AMR solutions could yield US$ 10–15 billion annual healthcare savings and US$ 35–40 billion in socio-economic costs in Asia Pacific. National action plans in countries such as Japan, South Korea, and Vietnam emphasize One Health approaches, creating avenues for colistin in regulated veterinary and human applications. This expansion is supported by manufacturing hubs in China and India, along with alliances focused on supply chain transparency and research and development into novel derivatives, potentially capturing growth in underserved markets such as Southeast Asia, where colistin remains essential for MDR outbreaks.

Asia Pacific Colistin Market Country Insights

By country, the Asia Pacific Colistin Market is segmented into Australia, Japan, Kazakhstan, and the Rest of APAC. The Rest of APAC held the largest share in 2025.

Singapore, India, Thailand, Malaysia, Vietnam, and the Philippines are among the major countries contributing to the colistin market in the Rest of Asia Pacific. The market in this region is driven by a rise in multidrug-resistant (MDR) Gram-negative infections in hospitals and livestock sectors, where colistin is a reserve antibiotic for bloodstream infections (BSI) and sepsis. According to the World Health Organization (WHO), the Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2023 shows carbapenem-resistant Enterobacterales rates exceeding 40% in countries such as India, Indonesia, Thailand, Malaysia, Philippines, and South Korea, driving the demand for colistin to treat lower respiratory tract infections (LRTI) and urinary tract infections (UTIs). In 2024, WHO data indicated a 6-12% increase in MDR Acinetobacter baumannii and Pseudomonas aeruginosa in these areas, boosting demand for colistin injectables (IV/IM) for ventilator-associated pneumonia (VAP). In 2025, the WHO projected continued high resistance, contributing to increased use of colistin for cystic fibrosis. New product developments include the WHO Regional Office for Southeast Asia's 2024 guidelines for colistin stewardship, promoting colistin-sparing alternatives like sulbactam-durlobactam in facilities in India and Thailand for tracheobronchitis. Other instances encompass national AMR plans in India, Indonesia, and Malaysia (2023-2025), which reported a 3-5% rise in colistin prescriptions for human health in 2024, according to respective ministries of health. The WHO Western Pacific Regional Office's 2025 AMR update supports nebulized inhalation solutions for VAP and topical formulations for skin infections via retail pharmacies. Additionally, the 2025 WHO One Health framework highlights oral formulations for animal health gastrointestinal infections through online pharmacies, addressing bowel decontamination amid rising MDR prevalence in the Rest of Asia Pacific.

Asia Pacific Colistin Market Company Profiles

Some of the key players operating in the market include Livzon Pharmaceutical Group Inc, TZF Polfa S.A., Tecoland Corporation, Fujian Lifecome Biochemistry Limited, Zhejiang Shenghua Biok Chemical Company Limited, Xellia Pharmaceuticals ApS, Shandong LuKang Pharmaceutical Co., Ltd, Apeloa Pharmaceutical Co., Ltd., Norma Hellas S.A, and Hebei Shengxue Dacheng Pharmaceutical Co., Ltd.

These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.

Asia Pacific Colistin Market Research Methodology

The following methodology has been followed for the collection and analysis of data presented in this report:

Secondary Research

The research process begins with comprehensive secondary research, utilizing internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:

• Company websites, annual reports, financial statements, broker analyses, and investor presentations
• Industry trade journals and other relevant publications
• Government documents, statistical databases, and market reports
• News articles, press releases, and webcasts specific to companies operating in the market

Note: All financial data included in the Company Profiles section has been standardized to US$. For companies reporting in other currencies, figures have been converted to US$ using the relevant exchange rates for the corresponding year.

Primary Research

The Insight Partners conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis and gain valuable insights. These research interviews are designed to:

• Validate and refine findings from secondary research
• Enhance the expertise and market understanding of the analysis team
• Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects

Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:

• Industry stakeholders: Vice Presidents, Business Development Managers, Market Intelligence Managers, and National Sales Managers
• External experts: Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise